在国内业务方面，联亚药业坦言，境内业务目前仍然处于起步阶段，形成销售收入的产品种类较少，公 司虽已经陆续有新产品在境内获批上市销售，且管线中储备了较多的拟上市产品，但由于部分在国内已 获批或审评中的产品目前尚未被纳入医保目录或集采清单，且部分在研产品市场规模较小，这在一定程 度上会影响相关产品在境内市场的推广和销售的速度及规模。 与此同时，联亚药业存在客户集中度较高的风险。据招股书数据，2022年度至2024年度，联亚药业向第 一大客户Ingenus销售收入占当期营业收入的比例分别为72.36%、56.63%和51.87%，Ingenus享有公司主 要产品琥珀酸美托洛尔缓释片、硝苯地平缓释片等在美国市场的独家经销权。Ingenus为一家注册于美 国的集研发、生产及销售于一体的综合型药企，主要从事仿制药的开发、制造和商业化，其业务与联亚 药业存在一定重合。 6月24日，南通联亚药业股份有限公司(下称"联亚药业")发布招股说明书，申请在深交所创业板IPO。联 亚药业主营高端仿制药业务，此前曾申请在上交所科创板IPO，于2024年9月主动撤回上市申请。 据招股书披露，联亚药业营收主要来源于美国市场，2023年起国内 ...

公司本次募集资金扣除发行费用后，将全部用于以下项目： | J | 1 | | --- | --- | | 1 | | | . | | | 車 117 1 | | | 1 U | 1 | | 序号 | | 项目名称 | 投资总额 | 拟使用本次募集资金金额 | | --- | --- | --- | --- | --- | | | 产业化基地 项目 | 生产基地建设项目 | 30,564.14 | 30,564.14 | | | | 研发中心建设项目 | 31,365.86 | 26,595.86 | | 2 | | 药物研发项目 | 32,840.00 | 32,840.00 | | 3 | | 补充流动资金 | 5,000.00 | 5,000.00 | | | | 合计 | 99,770.00 | 95,000.00 | 财务方面，于2022年度、2023年度及2024年度，联亚药业实现营业收入约为5.50亿元、7亿元、8.66亿元人民币；同期，公司实现净利润分别约为1.13 亿元、1.16亿元、2.60亿元人民币。 6月24日，南通联亚药业股份有限公司(简称：联亚药业)深交所创业板IPO已受理。中国国际 ...

4月29日晚间，前沿生物披露了2024年年报以及2025年一季度报告。报告显示，2024年前沿生物实现营业收入1.29亿元，同 比增长13.32%；今年一季度，公司实现营业收入2832.82万元，同比增长14.93%，收入继续保持增长态势。得益于积极推进降 本增效，2024年度公司经营活动产生的现金流量净支出较上年同期减少9465.55万元。 过去一年，全球生物科技产业在经济周期波动与技术变革的交织中加速演进，前沿生物始终以"市场引领、创新驱动"为初 心，在战略聚焦中稳健前行，为公司长期价值增长筑牢根基。 核心业务优势不断强化 作为一家研发驱动型的生物医药公司，前沿生物立足抗艾领域，致力于构建配方完整的长效抗艾产品矩阵。 与此同时，公司坚持差异化的市场推广策略，以高质量的循证医学依据为依托，在重点目标患者中展开针对性的宣传与渗 透。 据了解，前沿生物在长效多肽药物艾可宁®的开发过程中积累了扎实的技术实力和研发经验，基于长效多肽药物与小核酸 领域具备技术共通性，助力公司在小核酸领域的药物开发；公司与小核酸行业具备行业经验的上下游产业链企业积极合作，提 升技术竞争力。 基于技术优势与建立的专利壁垒，前沿生物布局的 ...

Core Viewpoint - Since the "14th Five-Year Plan," China's pharmaceutical industry has transitioned from a phase of rapid growth to a new stage of high-quality development, shifting from scale expansion to a coordinated improvement of scale and quality [1] Company Performance - In 2024, the company achieved a revenue of approximately 1.35 billion yuan, a year-on-year increase of 20.82%, and a net profit attributable to shareholders of 238 million yuan, up 5.15% year-on-year [2] - Excluding the impact of stock incentive expenses, the net profit attributable to shareholders and the net profit after deducting non-recurring gains and losses increased by 13.47% and 22.87% respectively [2] - The company's revenue from the formulation segment reached 1.077 billion yuan, a growth of 22.25%, while the raw material drug segment generated 121 million yuan, up 28.65% [2] Product Development - The company submitted 18 new formulation product registration applications in 2024 and obtained approvals for 13 new formulation products, including domestic first generics [3] - The company has a strong iterative capability in high-end generics, which continues to contribute to performance growth [3] - The company has completed the industrialization of six special narcotic products and has 16 products listed in the narcotic analgesic field, with over 20 products under research [3][4] R&D Investment - The company maintains a high R&D investment intensity, with 2024 R&D expenditure of approximately 290 million yuan, a year-on-year increase of 16.88%, accounting for 21.31% of revenue [4] - Since 2021, the proportion of R&D investment to revenue has consistently exceeded 20% [4] Internationalization Strategy - The company has made significant progress in internationalizing its raw materials, with several products receiving international approvals, including FDA and EU certifications [7] - The company has successfully commercialized its first product in the U.S. market, marking a breakthrough from 0 to 1 [7] Digital Transformation - In 2024, the company focused on a "digital intelligence" strategy, enhancing its industrial platform and achieving digital management across the entire drug research and production process [8] - The company has received certifications for data management and intelligent manufacturing capabilities, indicating progress in its digital transformation efforts [8] Future Outlook - In 2025, the company aims to accelerate its transformation from generics to innovation, positioning innovation as the core engine for high-quality development [8]